Disruption. It’s a buzzword that gets thrown around a lot by the media, pundits, and Wall Street. However, often, disruption never really comes. It takes a special trend or set of ingredients to make real disruption across a variety of industries happen. And we may be seeing that now.
We’re talking about the induction of GLP-1 agonist drugs.
Not only are these drugs being seen as a miracle cure to help treat diabetes, but analysts have now begun to speculate on the effects across a wide range of different sectors. Everything from retailers to travel could be affected. The question is how to separate fact from fiction. For investors that get this right, long-term profits could be had.
Get Premium to keep reading
This is a premium article. Please login to your Dividend.com Premium account to access this article.
Login Now
